GW Pharmaceuticals plc Reports First Quarter 2016 Financial Results
Feb. 10, 2016 02:59PM PST
BiotechGW Pharmaceuticals plc (NASDAQ:GWPH, AIM:GWP, AIM:GW) reported its financial results for the first quarter ended 31 December 2015.
GW Pharmaceuticals plc (NASDAQ:GWPH, AIM:GWP, AIM:GW) reported its financial results for the first quarter ended 31 December 2015.
According to the company:
RECENT OPERATIONAL HIGHLIGHTS
- Epidiolex® (CBD) childhood epilepsy program:
- Company sponsored Phase 3 development programs in Dravet syndrome and Lennox-Gastaut syndrome (LGS)
- First Phase 3 Dravet syndrome trial fully enrolled above original target sample size (120 randomized), data expected March 2016
- Second Phase 3 Dravet syndrome trial ongoing, data expected H2 2016
- Both LGS Phase 3 trials fully enrolled above original target sample sizes (171 for 2-arm, 225 for 3-arm randomized), data expected Q2 2016
- 97% transition rate of eligible patients from Phase 3 trials to long term open label extension
- NDA submission with FDA expected Q4 2016
- Phase 3 Tuberous Sclerosis Complex trial due to commence Q1 2016
- Additional clinical development for Epidiolex expected to commence in H2 2016
- Expanded access program
- Recent data update at the American Epilepsy Society December 2015 Annual Meeting showing promising safety and effectiveness consistent with prior updates
- Over 375 children and young adults on treatment at 22 U.S. clinical sites
- Over 900 children and young adults authorized for treatment by FDA under Expanded Access Treatment INDs and 6 U.S. State programs
- Advanced clinical programs in multiple cannabinoid pipeline product candidates:
- THCV Phase 2 study in type-2 diabetes data expected Q2 2016
- THC:CBD Phase 1b/2a study for the treatment of Recurrent Glioblastoma Multiforme (GBM) fully enrolled with data expected in mid-2016
- Orphan Drug Designation granted from FDA and EMA
- Sativex® Phase 2 study in spasticity due to cerebral palsy ongoing with data expected H2 2016
- CBDV Phase 2 partial-onset epilepsy study in adults ongoing. Part A complete and Part B underway with data expected around the end of 2016
- Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD Phase 1 clinical program expected to commence in H2 2016
- Orphan Drug and Fast Track Designations granted from FDA and EMA
- Clinical trials within the field of autism spectrum disorders expected to commence in H2 2016
- Pre-clinical progress addressing a number of areas of unmet need including autism spectrum disorders, Duchenne muscular dystrophy, glioma, ovarian and pancreatic cancers
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1807.40 | -11.42 | |
Silver | 20.28 | -0.46 | |
Copper | 3.68 | -0.10 | |
Palladium | 1938.50 | -23.50 | |
Platinum | 898.00 | -21.00 | |
Oil | 106.01 | -3.77 | |
Heating Oil | 3.86 | -0.10 | |
Natural Gas | 5.51 | -0.99 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â